CTX-10726 (a novel PD-1 x VEGF-A bispecific) is advancing as a new drug candidate after a year of preclinical development, with YE 2025 IND expected. Two Phase 2 biomarker trials are expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback